http://www.xconomy.com/national/2009/08/31/how-to-build-a-billion-dollar-company-and-keep-an-academic-day-job-according-to-david-walt/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 09:14:03 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/national/2009/08/31/how-to-build-a-billion-dollar-company-and-keep-an-academic-day-job-according-to-david-walt/comment-page-1/#comment-109456 Xconomy’s Biotech Predictions for 2010-2020 | MessagingLab Tue, 09 Feb 2010 03:09:55 +0000 http://www.xconomy.com/?p=39437#comment-109456 [...] of Chemistry at Tufts, co-founder of Illumina and subject of Luke Timmerman’s How to Build a Billion Dollar Company and Keep an Academic Day Job, offered the following 5 disruptive biotech ideas to watch: 1. Moore’s Law won’t be [...] [...] of Chemistry at Tufts, co-founder of Illumina and subject of Luke Timmerman’s How to Build a Billion Dollar Company and Keep an Academic Day Job, offered the following 5 disruptive biotech ideas to watch: 1. Moore’s Law won’t be [...]

]]> http://www.xconomy.com/national/2009/08/31/how-to-build-a-billion-dollar-company-and-keep-an-academic-day-job-according-to-david-walt/comment-page-1/#comment-82613 Skeptic Prof Fri, 18 Sep 2009 17:58:02 +0000 http://www.xconomy.com/?p=39437#comment-82613 Yikes, it worries me that the realistic pay off for high throughput science is being put on a "decades to hundreds" of years sort of timeline..."translational" approaches are starting to look a lot like "basic science". I hope we don't spend all of our money shoveling data into databases with a "someday" payoff...when smaller scale, hypothesis driven research often offers payoffs in short order. In less than a quarter century we have gone from Notch and Wingless in Drosophila to Notch and Wnt in cancer biology...real knowledge with genes whose deeply explored functions are giving real insight...what value exactly is the diabetes map...in a word where Rosetta is sold for parts after Merck says "meh". Just a little cheerleading for critical outcomes analysis folks...just cause NIH spends money doesn't mean good science is done. Yikes, it worries me that the realistic pay off for high throughput science is being put on a “decades to hundreds” of years sort of timeline…”translational” approaches are starting to look a lot like “basic science”. I hope we don’t spend all of our money shoveling data into databases with a “someday” payoff…when smaller scale, hypothesis driven research often offers payoffs in short order. In less than a quarter century we have gone from Notch and Wingless in Drosophila to Notch and Wnt in cancer biology…real knowledge with genes whose deeply explored functions are giving real insight…what value exactly is the diabetes map…in a word where Rosetta is sold for parts after Merck says “meh”. Just a little cheerleading for critical outcomes analysis folks…just cause NIH spends money doesn’t mean good science is done.

]]> http://www.xconomy.com/national/2009/08/31/how-to-build-a-billion-dollar-company-and-keep-an-academic-day-job-according-to-david-walt/comment-page-1/#comment-79078 First “consumer” purchases his genome sequence :: Now Possible Tue, 01 Sep 2009 13:14:37 +0000 http://www.xconomy.com/?p=39437#comment-79078 [...] to the Boston-based site Xconomy, San Diego-based Illumina (NASDAQ: ILMN) found its niche in the past decade by boosting the [...] [...] to the Boston-based site Xconomy, San Diego-based Illumina (NASDAQ: ILMN) found its niche in the past decade by boosting the [...]

]]>